I have always been focused on solving the puzzles related to Alzheimer’s disease and other psychiatric diseases, and before joining Roche I worked with Swissmedic, the Bill and Melinda Gates Foundation, several European universities, the EU Commission Directorate for Health and Food Safety, the World Health Organization, the CEOi and several Alzheimer’s disease Organizations. In 2018 and 2019 I have been nominated among the top 100 Women in Business in Switzerland.
阿尔茨海默氏症影响超过5000万people worldwide and this number is expected to increase in low and middle-income countries. It is a disease that begins decades before the symptoms become manifest. The signs of this pathology within the brain are detectable thanks to neuroimaging and fluid biomarkers. It is important to detect such signs before cognitive decline appears such as disease-modifying treatments can act before the damage is too advanced and irreversible. This is why Roche is working really hard to bring a real transformative solution to the way we manage this disease by introducing reliable CSF biomarkers to detect amyloid pathology, a hallmark of the disease, into the market and developing even novel ones to better characterize the pathology and patients characteristics. This will improve not only patient management but also clinical trial design and therefore clinical outcomes. At the same time, Roche is developing disease-modifying treatments which are a must if we want to defeat the last challenges and unmet needs in medicine, where even people like Bill Gates, decided to join the floor and defeat these conditions for which today we have no cure.
Being a pathologist, a neuroscientist who worked for years to find an immunotherapy for Alzheimer's disease and more importantly a doctor who spent years in a locked ward with people living with this devastating condition, it is a privilege for me to be within the Roche community in achieving the goal of making Alzheimer's disease a curable disease hopefully soon.
My work at Roche allows me to pursue my passion. Roche represents for me a unique platform to bring my medical and scientific competence at the disposal of the entire Alzheimer’s disease ecosystem and where patients are at the center.